BRUKINSA(BRUKINSA)组合显示,治疗慢性淋巴细胞白血病非常有效。 BeOne Medicines' BRUKINSA combo shows high efficacy in treating chronic lymphocytic leukemia.

据BeOne药物公司报告,该公司在Sequoia第三期试验中取得了成功的结果,该试验显示BRUKINSA (扎努布鲁丁尼布) 与venetoclax联合使用,即使在高危患者中也能有效治疗慢性淋巴细胞白血病 (CLL). BeOne Medicines has reported successful results from the Phase 3 SEQUOIA trial, showing BRUKINSA (zanubrutinib) in combination with venetoclax effectively treats chronic lymphocytic leukemia (CLL), even in high-risk patients. 合并的结果是,24个月的无累进性存活率达到92%,总体回复率为97%。 The combination achieved a 24-month progression-free survival rate of 92% and an overall response rate of 97%. 长期数据表明,对于17p删除的病人来说,5年无递增性存活率为72.2%,这突出表明BRUKINSA在为CLL治疗制定新标准方面的潜力。 Long-term data indicate a 5-year progression-free survival rate of 72.2% for patients with 17p deletions, highlighting BRUKINSA's potential in setting new standards for CLL treatment.